Zymeworks Inc. authorized a second 2026 share repurchase program of up to $200.0 million through 2028 and expects approximately $140.0 million in repurchases, following completion of an initial $125.0 million program.
ZYME · Zymeworks Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Zymeworks said Jazz's $3 to $5 billion Zannie peak-sales guidance implies potential royalty income of $500 million to $900 million, supporting a model combining internally funded R&D, strategic partnerships and investor-backed spin-offs.
Zymeworks reports unaudited pro forma combined results, in thousands, of $321,163 revenue and $11,766 net income following its September 23, 2026 acquisition of Theravance.
Zymeworks reported net income of $84.5 million for the nine months ended September 30, 2026 and expects existing cash plus a $250.0 million Jazz milestone payment received in October 2026 to fund operations for at least the next twelve months.
Zymeworks raised 2026 revenue guidance to $337 million to $351 million and adjusted EBITDA guidance to $176 million to $190 million. Third-quarter revenue reached $256.5 million, primarily on a $250.0 million Ziihera milestone following first-line HER2-positive GEA approval.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 153.02M | Nine Months Ended September 30, 2026 | — |
| Common shares outstanding | 69M | as of November 6, 2026 | — |
| Cumulative share repurchases ($) since August 2024 | $279.8M | since initiating share repurchase program in August 2024 | — |
| Cumulative shares repurchased since August 2024 | 12,940,827 | since initiating share repurchase program in August 2024 | — |
| Non-dilutive financing accessed during 2026 | $600M | during 2026 | — |
| Quarterly U.S. net sales of YUPELRI | $71.5M | 3Q 2026 | — |
| Royalty revenue from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne) | $2.3M | three months ended September 30, 2026 | — |
|
|
|||
| Share repurchases ($) | $14M | third quarter of 2026 | — |
| Share repurchases (shares) | 534,381 | third quarter of 2026 | — |
| Theravance Biopharma revenue contribution | $1.5M | during the quarter ended September 30, 2026 | — |
| Total share repurchases ($) | $140.4M | first nine months of 2026 | — |
| Total share repurchases (shares) | 5,737,790 | first nine months of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZYME
this stock
Zymeworks Inc.
|
$1.80B | -1.1% | +38.9% | 50.1 | 8.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 29
Zymeworks Inc. authorized a second 2026 share repurchase program of up to $200.0 million through 2028 and expects approximately $140.0 million in repurchases, following completion of an initial $125.0 million program.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZYME | -10.4% | -7.4% | +3.6% | -9.0% | -1.1% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -6.5% | -1.8% | +7.1% | -5.6% | -8.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.